Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > LATEST
LATEST
-
ARCHIVE Welfide: Business Forecasts Affected by Transfer of Business, Shares
January 15, 2001
-
ARCHIVE Sales of Takeda's Blopress Skyrocket: Top 100 Products Ranking
January 15, 2001
-
ARCHIVE Changing OTC Business Strategy, Priority Shifts to Volume Retailers
January 15, 2001
-
ARCHIVE NHI Price System Reform Shelved in Japan: US ITC Report
January 15, 2001
-
ARCHIVE OTC news on brief
January 15, 2001
-
ARCHIVE Growth of Morphine Consumption Slows Down
January 15, 2001
-
ARCHIVE Sankyo, Mochida Tie Up with Riken
January 15, 2001
-
ARCHIVE REGULATORY NEWS IN BRIEF -1-
January 15, 2001
-
ARCHIVE Asahi Chemical Invests US$9 Mil in Circe Biomedical
January 15, 2001
-
ARCHIVE Welfide Transfers Infusion Fluid Business to Otsuka Pharmaceutical Factory, Inc
January 15, 2001
-
ARCHIVE Elan Obtains Approval for Botulinum Toxin B in US
January 15, 2001
-
ARCHIVE Suntory, Taisho to Codevelop SUN N8075 for Cerebral Infarction
January 15, 2001
-
ARCHIVE NHI Medical Costs Map Not Reflecting Reality: JMARI
January 15, 2001
-
ARCHIVE Tanabe Licenses Out TR-14035 to SmithKline Beecham
January 15, 2001
-
COMMENTARY Advanced Technology and Segmentation of Companies
January 15, 2001
-
ARCHIVE Sumitomo Ties Up With Gene Logic
January 15, 2001
-
ARCHIVE Glaxo Wellcome Changes Its Name to Glaxo SmithKline, Relocates Head Office
January 15, 2001
-
COMMENTARY Don't Write Us Oldies Off!
January 15, 2001
-
ARCHIVE SBS Transfers Tagamet to Sumitomo
January 15, 2001
-
ARCHIVE Taisho Licenses CRF Receptor Antagonist to Janssen
January 1, 2001
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…